Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1

Chiho Konya, Yusuke Hatanaka, Yuuki Fujiwara, Kenko Uchida, Yoshitaka Nagai, Keiji Wada, Tomohiro Kabuta

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is an intracellular protein abundantly expressed in neurons, and a mutation in UCH-L1 has been identified in familial Parkinson's disease. UCH-L1 has been detected in human cerebrospinal fluid, raising the possibility that UCH-L1 is secreted from neurons. In the present study, we showed that a portion of UCH-L1 is secreted from cultured cells. The secretion of D30K UCH-L1, which lacks ubiquitin binding activity, was decreased compared with that of wild-type UCH-L1, while the secretion of C90S UCH-L1, which lacks hydrolase activity, was not. Treatment with Brefeldin A, an inhibitor of vesicle transport from the endoplasmic reticulum to the Golgi, did not block the secretion of UCH-L1, indicating that UCH-L1 is secreted by an unconventional pathway. The UCH-L1 sequence from Leu-32 to Leu-39 is similar to the unconventional secretory signal sequence of engrailed 2, and substitution of the leucines within this region (L32S/L32A/L34S/L34A/L39S/L39A) reduced the secretion of UCH-L1. We found that the Parkinson's disease-associated mutation I93M in UCH-L1 decreased the secretion of I93M UCH-L1. In addition, Parkinson's disease-linked α-synuclein mutants reduced the secretion of endogenous UCH-L1. Our results indicate that the hydrolase activity is not necessary for the unconventional secretion of UCH-L1, and suggest that the ubiquitin binding activity and the sequence between Leu-32 and Leu-39 are involved in the secretion. Moreover, the secretion of UCH-L1 could be involved in the pathology of Parkinson's disease.

    Original languageEnglish
    Pages (from-to)251-258
    Number of pages8
    JournalNeurochemistry International
    Volume59
    Issue number2
    DOIs
    Publication statusPublished - 2011 Aug

    Fingerprint

    Ubiquitin Thiolesterase
    Synucleins
    Parkinson Disease
    Mutation
    Hydrolases
    Ubiquitin

    Keywords

    • α-Synuclein
    • Parkinson's disease
    • UCH-L1
    • Unconventional secretion

    ASJC Scopus subject areas

    • Cellular and Molecular Neuroscience
    • Cell Biology

    Cite this

    Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1. / Konya, Chiho; Hatanaka, Yusuke; Fujiwara, Yuuki; Uchida, Kenko; Nagai, Yoshitaka; Wada, Keiji; Kabuta, Tomohiro.

    In: Neurochemistry International, Vol. 59, No. 2, 08.2011, p. 251-258.

    Research output: Contribution to journalArticle

    Konya, Chiho ; Hatanaka, Yusuke ; Fujiwara, Yuuki ; Uchida, Kenko ; Nagai, Yoshitaka ; Wada, Keiji ; Kabuta, Tomohiro. / Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1. In: Neurochemistry International. 2011 ; Vol. 59, No. 2. pp. 251-258.
    @article{f908a313f1ab497a9c116629af5d281e,
    title = "Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1",
    abstract = "Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is an intracellular protein abundantly expressed in neurons, and a mutation in UCH-L1 has been identified in familial Parkinson's disease. UCH-L1 has been detected in human cerebrospinal fluid, raising the possibility that UCH-L1 is secreted from neurons. In the present study, we showed that a portion of UCH-L1 is secreted from cultured cells. The secretion of D30K UCH-L1, which lacks ubiquitin binding activity, was decreased compared with that of wild-type UCH-L1, while the secretion of C90S UCH-L1, which lacks hydrolase activity, was not. Treatment with Brefeldin A, an inhibitor of vesicle transport from the endoplasmic reticulum to the Golgi, did not block the secretion of UCH-L1, indicating that UCH-L1 is secreted by an unconventional pathway. The UCH-L1 sequence from Leu-32 to Leu-39 is similar to the unconventional secretory signal sequence of engrailed 2, and substitution of the leucines within this region (L32S/L32A/L34S/L34A/L39S/L39A) reduced the secretion of UCH-L1. We found that the Parkinson's disease-associated mutation I93M in UCH-L1 decreased the secretion of I93M UCH-L1. In addition, Parkinson's disease-linked α-synuclein mutants reduced the secretion of endogenous UCH-L1. Our results indicate that the hydrolase activity is not necessary for the unconventional secretion of UCH-L1, and suggest that the ubiquitin binding activity and the sequence between Leu-32 and Leu-39 are involved in the secretion. Moreover, the secretion of UCH-L1 could be involved in the pathology of Parkinson's disease.",
    keywords = "α-Synuclein, Parkinson's disease, UCH-L1, Unconventional secretion",
    author = "Chiho Konya and Yusuke Hatanaka and Yuuki Fujiwara and Kenko Uchida and Yoshitaka Nagai and Keiji Wada and Tomohiro Kabuta",
    year = "2011",
    month = "8",
    doi = "10.1016/j.neuint.2011.05.012",
    language = "English",
    volume = "59",
    pages = "251--258",
    journal = "Neurochemistry International",
    issn = "0197-0186",
    publisher = "Elsevier Limited",
    number = "2",

    }

    TY - JOUR

    T1 - Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1

    AU - Konya, Chiho

    AU - Hatanaka, Yusuke

    AU - Fujiwara, Yuuki

    AU - Uchida, Kenko

    AU - Nagai, Yoshitaka

    AU - Wada, Keiji

    AU - Kabuta, Tomohiro

    PY - 2011/8

    Y1 - 2011/8

    N2 - Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is an intracellular protein abundantly expressed in neurons, and a mutation in UCH-L1 has been identified in familial Parkinson's disease. UCH-L1 has been detected in human cerebrospinal fluid, raising the possibility that UCH-L1 is secreted from neurons. In the present study, we showed that a portion of UCH-L1 is secreted from cultured cells. The secretion of D30K UCH-L1, which lacks ubiquitin binding activity, was decreased compared with that of wild-type UCH-L1, while the secretion of C90S UCH-L1, which lacks hydrolase activity, was not. Treatment with Brefeldin A, an inhibitor of vesicle transport from the endoplasmic reticulum to the Golgi, did not block the secretion of UCH-L1, indicating that UCH-L1 is secreted by an unconventional pathway. The UCH-L1 sequence from Leu-32 to Leu-39 is similar to the unconventional secretory signal sequence of engrailed 2, and substitution of the leucines within this region (L32S/L32A/L34S/L34A/L39S/L39A) reduced the secretion of UCH-L1. We found that the Parkinson's disease-associated mutation I93M in UCH-L1 decreased the secretion of I93M UCH-L1. In addition, Parkinson's disease-linked α-synuclein mutants reduced the secretion of endogenous UCH-L1. Our results indicate that the hydrolase activity is not necessary for the unconventional secretion of UCH-L1, and suggest that the ubiquitin binding activity and the sequence between Leu-32 and Leu-39 are involved in the secretion. Moreover, the secretion of UCH-L1 could be involved in the pathology of Parkinson's disease.

    AB - Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is an intracellular protein abundantly expressed in neurons, and a mutation in UCH-L1 has been identified in familial Parkinson's disease. UCH-L1 has been detected in human cerebrospinal fluid, raising the possibility that UCH-L1 is secreted from neurons. In the present study, we showed that a portion of UCH-L1 is secreted from cultured cells. The secretion of D30K UCH-L1, which lacks ubiquitin binding activity, was decreased compared with that of wild-type UCH-L1, while the secretion of C90S UCH-L1, which lacks hydrolase activity, was not. Treatment with Brefeldin A, an inhibitor of vesicle transport from the endoplasmic reticulum to the Golgi, did not block the secretion of UCH-L1, indicating that UCH-L1 is secreted by an unconventional pathway. The UCH-L1 sequence from Leu-32 to Leu-39 is similar to the unconventional secretory signal sequence of engrailed 2, and substitution of the leucines within this region (L32S/L32A/L34S/L34A/L39S/L39A) reduced the secretion of UCH-L1. We found that the Parkinson's disease-associated mutation I93M in UCH-L1 decreased the secretion of I93M UCH-L1. In addition, Parkinson's disease-linked α-synuclein mutants reduced the secretion of endogenous UCH-L1. Our results indicate that the hydrolase activity is not necessary for the unconventional secretion of UCH-L1, and suggest that the ubiquitin binding activity and the sequence between Leu-32 and Leu-39 are involved in the secretion. Moreover, the secretion of UCH-L1 could be involved in the pathology of Parkinson's disease.

    KW - α-Synuclein

    KW - Parkinson's disease

    KW - UCH-L1

    KW - Unconventional secretion

    UR - http://www.scopus.com/inward/record.url?scp=79960376333&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79960376333&partnerID=8YFLogxK

    U2 - 10.1016/j.neuint.2011.05.012

    DO - 10.1016/j.neuint.2011.05.012

    M3 - Article

    VL - 59

    SP - 251

    EP - 258

    JO - Neurochemistry International

    JF - Neurochemistry International

    SN - 0197-0186

    IS - 2

    ER -